BR112022007313A2 - Conjugado de um agente quelante, e, radiofármaco - Google Patents

Conjugado de um agente quelante, e, radiofármaco

Info

Publication number
BR112022007313A2
BR112022007313A2 BR112022007313A BR112022007313A BR112022007313A2 BR 112022007313 A2 BR112022007313 A2 BR 112022007313A2 BR 112022007313 A BR112022007313 A BR 112022007313A BR 112022007313 A BR112022007313 A BR 112022007313A BR 112022007313 A2 BR112022007313 A2 BR 112022007313A2
Authority
BR
Brazil
Prior art keywords
chelating agent
muc5ac
radiodrug
conjugate
antibody
Prior art date
Application number
BR112022007313A
Other languages
English (en)
Inventor
Nakata Norihito
Kobashi Nobuya
Shoyama Yoshinari
Matono Mitsuhiro
Ochiai Yasushi
Murakami Takayuki
Original Assignee
Nihon Mediphysics Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd, Sumitomo Pharma Co Ltd filed Critical Nihon Mediphysics Co Ltd
Publication of BR112022007313A2 publication Critical patent/BR112022007313A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nuclear Medicine (AREA)

Abstract

CONJUGADO DE UM AGENTE QUELANTE, E, RADIOFÁRMACO. O anticorpo humanizado anti-MUC5AC marcado com RI é um complexo de um agente quelante quelatado por radionuclídeo e um anticorpo (o radionuclídeo é um nuclídeo metálico que emite raios a ou pósitrons, e o anticorpo é um anticorpo humanizado que se liga especificamente a MUC5AC) e é muito útil no tratamento e/ou diagnóstico de doenças nas quais MUC5AC é superexpressa, especialmente câncer, devido à excelente especificidade para MUC5AC e capacidade de se acumular em tumores.
BR112022007313A 2019-10-18 2020-10-16 Conjugado de um agente quelante, e, radiofármaco BR112022007313A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019191562 2019-10-18
PCT/JP2020/039074 WO2021075544A1 (ja) 2019-10-18 2020-10-16 Ｒｉ標識されたヒト化抗体

Publications (1)

Publication Number Publication Date
BR112022007313A2 true BR112022007313A2 (pt) 2022-07-05

Family

ID=75538071

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007313A BR112022007313A2 (pt) 2019-10-18 2020-10-16 Conjugado de um agente quelante, e, radiofármaco

Country Status (13)

Country Link
US (2) US11369701B2 (pt)
EP (1) EP4049684A4 (pt)
JP (2) JP7036996B2 (pt)
KR (1) KR20220084135A (pt)
CN (1) CN114585393B (pt)
AU (1) AU2020367415A1 (pt)
BR (1) BR112022007313A2 (pt)
CA (1) CA3158322A1 (pt)
IL (1) IL292133A (pt)
MX (1) MX2022004582A (pt)
TW (1) TW202128230A (pt)
WO (1) WO2021075544A1 (pt)
ZA (1) ZA202205226B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233247A (zh) * 2020-10-16 2022-09-01 日商日本醫事物理股份有限公司 抗ｈｅｒ２抗體之放射性複合體及放射性醫藥
WO2022224980A1 (ja) * 2021-04-20 2022-10-27 日本メジフィジックス株式会社 抗ｃｄ２０抗体の放射性複合体、及び、放射性医薬
JPWO2022225006A1 (pt) * 2021-04-21 2022-10-27
WO2023157822A1 (ja) * 2022-02-15 2023-08-24 日本メジフィジックス株式会社 抗ｖｅｇｆ抗体の放射性複合体、及び、放射性医薬
WO2024090488A1 (ja) * 2022-10-26 2024-05-02 日本メジフィジックス株式会社 放射性医薬組成物
WO2024090489A1 (ja) * 2022-10-26 2024-05-02 日本メジフィジックス株式会社 放射性医薬組成物の製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07203974A (ja) 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
JPH115749A (ja) 1997-06-13 1999-01-12 Tosoh Corp 癌治療医薬品組成物
US8435529B2 (en) * 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
SE0200943D0 (sv) 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
CN102137681B (zh) * 2008-08-08 2014-12-03 埃姆诺医药有限公司 抗胰腺癌抗体
AU2011230313B2 (en) 2010-03-24 2015-01-22 Kaneka Corporation Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157102A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
US9107960B2 (en) * 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US20160303258A1 (en) 2013-12-03 2016-10-20 Millennium Pharmaceuticals, Inc. Compounds and compositions for imaging gcc-expressing cells
WO2016003869A1 (en) * 2014-06-30 2016-01-07 Immunomedics, Inc. Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
KR102651537B1 (ko) 2015-05-20 2024-03-25 가고시마 유니버시티 IgG 결합 펩타이드에 의한 항체의 특이적 변형
JP6959616B2 (ja) * 2016-06-13 2021-11-02 国立大学法人 鹿児島大学 ＩｇＧ結合ペプチドによる部位特異的ＲＩ標識抗体
JP7191938B2 (ja) * 2017-05-05 2022-12-19 センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション Ｉｇｆ－１ｒモノクローナル抗体及びその使用
WO2018230257A1 (ja) 2017-06-16 2018-12-20 国立大学法人鹿児島大学 ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
US11701440B2 (en) 2018-04-16 2023-07-18 Nihon Medi-Physics Co., Ltd. Modified antibody and radioactive metal-labelled antibody
JP7242325B2 (ja) 2018-04-20 2023-03-20 キヤノン株式会社 画像形成装置
TW202123969A (zh) * 2019-10-18 2021-07-01 日商大日本住友製藥股份有限公司 人類化抗體或其抗原結合片段、此等之製造方法及用途

Also Published As

Publication number Publication date
CA3158322A1 (en) 2021-04-22
AU2020367415A1 (en) 2022-05-19
WO2021075544A1 (ja) 2021-04-22
CN114585393A (zh) 2022-06-03
JP7036996B2 (ja) 2022-03-15
US20210338852A1 (en) 2021-11-04
US11369701B2 (en) 2022-06-28
TW202128230A (zh) 2021-08-01
MX2022004582A (es) 2022-07-21
KR20220084135A (ko) 2022-06-21
JP2022088398A (ja) 2022-06-14
ZA202205226B (en) 2023-11-29
EP4049684A4 (en) 2023-10-25
EP4049684A1 (en) 2022-08-31
CN114585393B (zh) 2024-08-13
IL292133A (en) 2022-06-01
US20230094773A1 (en) 2023-03-30
JPWO2021075544A1 (ja) 2021-11-04

Similar Documents

Publication Publication Date Title
BR112022007313A2 (pt) Conjugado de um agente quelante, e, radiofármaco
BR112018067522A2 (pt) anticorpos específicos para receptor de poliovírus humano (pvr)
BR112021011431A2 (pt) Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
BR112022021322A2 (pt) Anticorpo contra nectina-4 e aplicação do mesmo
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
BR112018070636A2 (pt) método de tratamento de um sujeito humano que tem câncer, anticorpo, uso de um anticorpo, anticorpo para uso, combinação de um anticorpo, kit para uso no tratamento de câncer, composição farmacêutica, anticorpo biespecífico, método para tratamento de câncer, anticorpo biespecífico para uso e método de depleção de células t reguladoras em um tumor sólido em um sujeito
BR112021007902A2 (pt) Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
BR112018073574A2 (pt) conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
BR112019000071A2 (pt) conjugados adjuvantes de anticorpo
DOP2021000238A (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
BR112017021245A2 (pt) Anticorpo anti-c-met e conjugado anticorpo anti- c-met-fármaco citotóxico e uso farmacêutico do mesmo
BR112013004056B8 (pt) Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
BR112012016820A2 (pt) Metodos para tratamento de cancer de seio
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
CU24644B1 (es) Conjugados anticuerpo-fármaco para ablación de células madre hematopoyéticas
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS